Neutralizing Antibodies during Treatment with Interferon Beta-1b in 1745 Patients with Relapsing-Remitting Multiple Sclerosis

被引：0
|
作者：
Goodin, Douglas
O'Connor, Paul
Hartung, Hans P.
Kappos, Ludwig
Arnason, Barry
Comi, Giancarlo
Cook, Stuart
Filippi, Massimo
Jeffery, Douglas
Bogumil, Timon
Sandbrink, Rupert
Beckmann, Karola
Boateng, Francis
Pohl, Christoph
机构：
来源：
NEUROLOGY | 2009年 / 72卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A317 / A318
页数：2
相关论文
共 50 条
  • [1] Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis
    Petkau, J
    White, R
    [J]. MULTIPLE SCLEROSIS, 1997, 3 (06): : 402 - 402
  • [2] Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
    Petkau, AJ
    White, RA
    Ebers, GC
    Reder, AT
    Sibley, WA
    Lublin, FD
    Paty, DW
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (02) : 126 - 138
  • [3] Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy
    Lanzillo, R.
    Orefice, G.
    Prinster, A.
    Ventrella, G.
    Liuzzi, R.
    Scarano, V.
    Florio, C.
    Vacca, G.
    Brunetti, A.
    Alfano, B.
    Morra, V. Brescia
    Bonavita, V.
    [J]. NEUROLOGICAL SCIENCES, 2011, 32 (02) : 287 - 292
  • [4] Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy
    R. Lanzillo
    G. Orefice
    A. Prinster
    G. Ventrella
    R. Liuzzi
    V. Scarano
    C. Florio
    G. Vacca
    A. Brunetti
    B. Alfano
    V. Brescia Morra
    V. Bonavita
    [J]. Neurological Sciences, 2011, 32 : 287 - 292
  • [5] Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis
    Deisenhammer, F
    Giovannoni, G
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (06)
  • [6] Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain
    Arbizu, T
    Alvarez-Cermeño, JC
    Decap, G
    Fernández, O
    Uría, DF
    Merino, AG
    Izquierdo, G
    Montalbán, X
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2000, 102 (04): : 209 - 217
  • [7] Interferon beta-1b in relapsing-remitting multiple sclerosis: the effect of disease duration on treatment efficacy
    Rusek, S.
    Hozejowski, R.
    Tutaj, A.
    Kozlowska-Boszko, B.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 257 - 257
  • [8] The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
    Paolicelli, Damiano
    Iannazzo, Sergio
    Santoni, Laura
    Iaffaldano, Antonio
    Di Lecce, Valentina
    Manni, Alessia
    Lavolpe, Vito
    Tortorella, Carla
    D'Onghia, Mariangela
    Direnzo, Vita
    Puma, Elisa
    Trojano, Maria
    [J]. PLOS ONE, 2016, 11 (07):
  • [9] A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b
    Ricci, A
    Cucci, A
    Rovera, A
    Clerico, M
    Durelli, L
    [J]. NEUROLOGY, 2006, 66 (05) : A236 - A236
  • [10] Health economic evaluation of interferon beta-1a versus interferon beta-1b for patients with relapsing-remitting multiple sclerosis in Switzerland
    Nuijten, M. J. C.
    Chofflon, M.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 : S262 - S262
12345